

Oxford Genome Sciences Recruits Senior Industry Professionals to Drive its Development of Novel Personalised Medicines

Establishes its Own US Operations

Oxford, UK, 18 April 2007. Oxford Genome Sciences (UK) Ltd “OGeS” announces today that it has appointed several senior pharmaceutical industry professionals as it builds its organisation to support its development of novel personalised medicines. In the UK, the company has strengthened its in-house drug and biomarker discovery capabilities while in the US it has established a pre-clinical group that will provide support to the development of company’s own product portfolio. OGeS is focused on developing new personalised medicines for the treatment of cancer based on capitalising on its Oxford Genome Anatomy Project (OGAP®), which is one of the world’s largest proprietary collection of proteins with relevance to clinical medicine.

The two new recruits to the OGeS team in the UK are:

Dr Benjamin Reed has joined OGeS’ Biomarker Services Division as Business Development Director. Dr Reed previously worked at Ciphergen Biosystems for 6 years and has extensive knowledge and experience in the field of biomarker discovery. He was responsible for providing proteomics equipment as well as analytical services to academic institutes and pharmaceutical and biotechnology companies.

Dr David Bell PhD, has joined OGeS as Head of Mass Spectrometry Operations. Dr Bell has joined the company from Glaxo SmithKline where he worked for 18 years. At Glaxo SmithKline, he developed and applied mass spectrometric methods to drug discovery and development processes. He has experience of a wide range of instrumentation, particularly LC/MS/MS & applications in the pharmaceutical industry. Latterly, he was involved in biomarker discovery and target identification using a range of proteomics approaches.

David has co-authored over 20 publications on the utilization of mass spectrometry in pharmaceutical R&D.

In the US, OGeS has established a pre-clinical group in San Francisco in order to leverage its existing strategic alliances with Medarex and Biosite and to advance the company growing oncology antibodies portfolio. The group will initially consist of a group of three experienced drug discovery and development professionals providing and building our preclinical development capacity. It will be headed by Dr Mike Gresser, who has recently joined the company’s Scientific Advisory Board.

The other two members of the pre-clinical group in the US are:

Dr David Fitzpatrick will lead the Preclinical Development team. Dr Fitzpatrick has extensive industry experience including seven years at Immunex and Amgen. His pre-clinical expertise includes several therapeutic antibody projects in asthma, arthritis and psoriasis, which he and his group helped advance into Phase I clinical trials. David has also spent more than 10 years undertaking biomedical research in Australia and Canada.

Dr Beatrice Perotti will lead the Preclinical Development Programs and be in charge of the business operations of the US Office of OGeS. Dr Perotti had received her PhD from UCSF

and MBA from UCLA, and spent 13 years at Pfizer Central Research and Amgen Inc. Beatrice has broad experiences including early development team leadership and has led functional teams, as well as cross-functional matrix teams in both development and corporate business projects.

Dr Christian Rohlf, CEO of OGeS commenting on today's announcement said:

"I am delighted that we have been able to attract such a group of highly experienced industry professionals on both sides of the Atlantic to the OGeS. We are at a very exciting point in our development as our recent deals with both Biosite and Medarex have allowed us to make significant progress towards our goal of developing personalised treatment regimes for patients with cancer. With our new expanded drug and biomarker discovery capabilities and our newly formed pre-clinical group in the United States we are now in a position to support further additional partnership deals which will allow us to convert the unique information in our OGAP database into additional diagnostics and therapeutics that will be of benefit to patients with cancer."

- END -

About Oxford Genome Sciences

Oxford Genome Sciences (OGeS) is focused on the development of personalised medicines, mainly for oncology indications and Alzheimer's disease. The company has developed a unique integrated platform that combines genomic, proteomic and clinical information to accelerate the discovery and validation of drug targets and biomarkers in human beings. OGeS believes the benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating more accurate drug development and providing cost and time savings.

OGeS's strategy is to enter into flexible strategic alliances to capture maximum value from its unique and integrated platform for the development of new therapeutics and diagnostics in the field of cancer and Alzheimer's disease. The company has signed a number of collaborations in the area of colorectal cancer (CRC), which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of CRC. Specifically, OGeS has entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers including CRC and with Biosite to develop a new diagnostic protein panel for relapsing CRC. In parallel, OGeS provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies providing OGeS with short-term revenues.

OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP®

Oxford Genome Anatomy Project (OGAP) holds one of the world's largest proprietary collection of proteins represented by the database, which contains over one million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.

OGAP® is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see www.oxfordgenomesciences.com

Contacts:

Oxford Genome Sciences
Dr Christian Rohlff, Chief Executive Officer
Tel: +44 (0)1235 861770
christian.rohlff@oxfordgenomesciences.com

Citigate Dewe Rogerson
David Dible, Valerie Auffray
Tel: +44 (0)207 638 9571
valerie.auffray@citigatedr.co.uk